Latest Immunosuppressants Stories

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

2013-05-15 00:21:05

Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials PARIS and TARRYTOWN, N.Y., May 15, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled...

Novel Drug Treatment Quickly Reverses Traumatic Brain Injury

2013-05-09 23:49:11

Neurological Wellness Center Responds to a Recent Report; “Brain Injury Awareness Month: New Hope for the Brain-Injured Person.”* (PRWEB) May 08, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from traumatic brain injury since 2010. March was Brain Injury Awareness Month. Traumatic Brain Injury (TBI) is a serious problem in the United States according to this article in the Huffington Post. 1.7 million Americans will experience a...

Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis

2013-05-10 00:20:42

Ilaris® (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection(1) EAST HANOVER, N.J., May 10, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris(®) (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the...

Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million

2013-05-10 00:20:38

Jury ruled Abbott was Negligent in Alerting Doctors About the Increased Risks of Fungal Infections Associated with Humira CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdict finding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his wife, Delores Tietz. The court entered judgment in that sum, plus costs, in favor of the Plaintiff. This is the first Humira lawsuit filed against Abbott to go to trial....

The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis

2013-05-02 08:39:04

For the Treatment of Severe Ulcerative Colitis, Remicade Holds a Strong Lead Over Humira, According to a New Report from BioTrends Research Group EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United...

Alzheimer's Treatment Clinical Trial Receives Clearance

2013-05-01 23:00:26

Neurological Wellness Center to launch a clinical trial of perispinally administered etanercept as an Alzheimer's disease treatment. (PRWEB) May 01, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's disease since 2010. Although the precise causes of Alzheimer's Disease are still unknown, there is a growing body of evidence linking chronic inflammatory events in the brain with the onset and progression of AD....

Vedolizumab Has the Potential to Offer Improvement Over Infliximab in Maintaining Remission in Moderate to Severe Ulcerative Colitis

2013-04-29 08:28:34

Gastroenterologists in the U.S. and EU5 Agree that Improved Maintenance of Remission is One of the Greatest Unmet Needs, According to a New Report from Decision Resources BURLINGTON, Mass., April 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies that offer improved effect on...

Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro(TM) for Treatment of Kidney Transplant Patients

2013-04-29 08:27:28

HORSHOLM, Denmark, April 29, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro Phase III 3001 study in stable kidney transplant patients and data from an...

Topical Use Of Arthritis Drug Provides Relief For Dry Eye Disease

2013-04-19 16:27:28

Research study online in JAMA Ophthalmology may herald new era of new highly targeted molecular treatment for common condition Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life. An estimated nine million people in the United State alone suffer from significant DED; millions more may have milder forms or experience discomfort when exposed to low humidity...

Novel Drug Treatment Quickly Reverses Alzheimer’s Disease Resulting in a Significant Reduction in Assisted Living Expenses

2013-04-17 23:04:47

Neurological Wellness Center Comments on Alzheimer’s Care Assisted Living Expenses Costing $90 to $200 Per Day According to a Recent Article in the Los Angeles Times* (PRWEB) April 17, 2013 Implementing the treatment detailed in Perispinal etanercept: a new therapeutic paradigm in neurology by Dr. Tobinick can enable a severely impaired person needing full time assisted living care who is unable to recognize their own children or even count to ten to, after a single dose, recognize...